The second sitting of the House of Lords Science and Technology Committee inquiry into the Life Sciences Industrial Strategy will be held on 17th October 2017.
The meeting will comprise three evidence sessions, during which the Committee will question representatives from:
- Global pharmaceutical leaders, GSK and AstraZeneca, about the contribution large pharmaceutical companies can, should, and will make to the implementation of the strategy and the attractiveness of the UK as place for businesses to invest in life sciences
- Small and medium-sized enterprises (SMEs), Randox Laboratories, Inhealthcare and Matoke Holdings, about the challenges smaller companies face, such as funding and innovation
- Healthcare regulatory and advice bodies, the National Institute for Health and Care Excellence (NICE) and the Medicines and Healthcare Products Regulatory Agency (MHRA), about the potential impact of differing regulations between the UK and the EU after Brexit, and whether regulators should do more to aid the uptake of innovative products by the NHS.
Questions likely to be covered in the sessions include:
- What is your experience of getting innovations in treatments and devices taken up by the NHS?
- What is your experience of accessing different sources of funding to grow your company?
- What are your overall impressions of the Life Sciences Industrial Strategy and to what extent were your organisations involved in its preparation?
- Are there any aspects of regulation that are proving a block to the taking of science to innovation and commercialisation?